Compounds > mifepristone
Page last updated: 2024-08-23

mifepristone and Weight Loss

mifepristone has been researched along with Weight Loss in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Pfalzgraff, T; Skov, PV1
Andrews, ZB; Cowley, MA; Dodd, GT; Eramo, M; Henry, BA; Mitchell, CA; Tiganis, T; Xirouchaki, CE1
Bakhos, JJ; Bou Khalil, R; Farès, N; Hajal, J; Richa, S; Saliba, Y; Smayra, V; Souaiby, L; Tamraz, J1
Alexander-Chacko, J; Barr, RJ; Carson, MW; Coghlan, M; Gehlert, DR; Morin, M; Need, A; Shaw, J; Sindelar, DK1
Cram, D; Fein, HG; Kushner, H; Nguyen, D; Vaughan, TB1
Agarwal, MK; Lazar, G1

Other Studies

6 other study(ies) available for mifepristone and Weight Loss

ArticleYear
Combined antagonist treatment of glucocorticoid and mineralocorticoid receptor does not affect weight loss of fasting rainbow trout but inhibits a fasting-induced elevation of cortisol secretion.
    Comparative biochemistry and physiology. Part A, Molecular & integrative physiology, 2022, Volume: 274

    Topics: Animals; Fasting; Glucocorticoids; Hydrocortisone; Mifepristone; Mineralocorticoid Receptor Antagonists; Oncorhynchus mykiss; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone; Weight Loss

2022
Intranasal Targeting of Hypothalamic PTP1B and TCPTP Reinstates Leptin and Insulin Sensitivity and Promotes Weight Loss in Obesity.
    Cell reports, 2019, Sep-10, Volume: 28, Issue:11

    Topics: Adipose Tissue, White; Administration, Intranasal; Animals; Blood-Brain Barrier; Cholestanes; Diet, High-Fat; Feeding Behavior; Gliosis; Glucocorticoids; Hypothalamus; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mifepristone; Obesity; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Spermine; Weight Loss

2019
Mifepristone reduces hypothalamo-pituitary-adrenal axis activation and restores weight loss in rats subjected to dietary restriction and methylphenidate administration.
    Neuroscience research, 2018, Volume: 135

    Topics: Adiponectin; Animals; Brain; Caloric Restriction; Central Nervous System Stimulants; Female; Hormone Antagonists; Hypothalamo-Hypophyseal System; Interleukin-6; Methylphenidate; Mifepristone; Pituitary-Adrenal System; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Weight Loss

2018
LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gain in rats.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 348, Issue:1

    Topics: Animals; Antipsychotic Agents; Aza Compounds; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Female; HEK293 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Male; Mice; Mice, Inbred C57BL; Mifepristone; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Sulfonamides; Weight Gain; Weight Loss

2014
Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.
    BMC endocrine disorders, 2015, Oct-27, Volume: 15

    Topics: Adult; Aged; Cushing Syndrome; Female; Follow-Up Studies; Hormone Antagonists; Humans; Male; Middle Aged; Mifepristone; Prognosis; Receptors, Glucocorticoid; Time Factors; Weight Loss

2015
The antiglucocorticoid RU 38486 reverses the wasting syndrome in newborn rats.
    Die Naturwissenschaften, 1992, Volume: 79, Issue:10

    Topics: Animals; Animals, Newborn; Growth; Hydrocortisone; Mifepristone; Rats; Rats, Wistar; Syndrome; Weight Loss

1992